Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SCHOLIUM GROUP PLC. We currently have 1 research reports from 1 professional analysts.
|09Dec16 09:58||RNS||Holding(s) in Company|
|30Nov16 07:00||RNS||Interim Report and Financial Statements|
|13Oct16 07:00||RNS||Trading Statement|
|09Sep16 11:11||RNS||Result of AGM|
|14Jul16 13:44||RNS||Notice of AGM|
|07Jul16 07:00||RNS||Annual Report & Financial Statements|
|13May16 07:00||RNS||Trading Update|
Frequency of research reports
Research reports on
SCHOLIUM GROUP PLC
SCHOLIUM GROUP PLC
Small Cap Breakfast
30 Nov 16
Asia Pacific Investment Partner - The research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas - Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group - UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Gym Group - Not quite a lean, fit & healthy outlook
15 Feb 17
Gym Group has done an excellent job in successfully rolling out a disruptive business model in the health & fitness market. However, we think growth expectations are too high and the shares look expensive on a FY17 P/E of 27x. We expect initial signs of increased competition / cannibalisation and LFL pressure to increase over the next 2-3 years and the shares to de-rate. We pitch our forecasts 5%-14% below consensus and initiate with a Sell recommendation and a 145p target price.
Panmure Morning Note 24-02-2017
24 Feb 17
Upgrades and increased shareholder returns were needed to justify the recent share price rally: they have been duly delivered and we expect a positive response today. FY16 was largely ‘in-line’ and initial FY17 comments, for operating profit growth YOY, are encouraging. Our initial estimate is for consensus upgrades of 5-10%. IAG has confirmed a €500m share buy-back programme, which was well flagged and we think in line with market expectations. Overall a welcome, slightly more positive read for the sector, particularly those with self-help levers. Presentation 9am GMT.
Cycle pains; structural gains
01 Feb 17
A downgrade is a downgrade, which we put through in this note (FY17 net profit -8%). The fare softness behind it is not worrisome to us, reflecting a tough point in the cycle, with industry supply/demand imbalance driving revenue yields down across the sector. Wizz Air is not immune but its own yield softness is partly self-inflicted, with management taking an aggressive capacity stance to capitalise on structural growth opportunities. This may be dilutive to near-term earnings, but should be accretive to medium-term growth and shareholder value. Experience suggests these are exactly the time to buy airline winners, which we believe Wizz Air is becoming. Limited stock liquidity can move the price up quickly as well as down. Reiterate BUY, TP unchanged at 2,300p.